# Alvotech share price today (Alvotech, ALVO)

> Alvotech's balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. ALVO · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/alvo

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $4.54 (−40.7% in a year)
- P/E: 58.0× (higher than 84% of the last 1 year)
- Revenue (Jun 2026): $106 M (−38.9% on a year ago)
- Profit (Jun 2026): −$66.8 M (−308.6% on a year ago)
- Operating margin: −11.1% (−21.5 points on a year ago)
- ROE: −10%, FY25

Biggest thing to watch: the P/E is higher than 84% of its own history, so the multiple has already done part of the work. ## What is the Alvotech share price today? Alvotech's share price was $4.54 at the close on 3 November 2026. That is 8.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $6, and at that close it sat 53% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 15 weeks in a row. Over the last 1 year the share price moved −47% while the S&P 500 moved +21%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Alvotech pay? Alvotech pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Alvotech on? Alvotech is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Alvotech profitable? Alvotech posted a net loss of $66.8 M in the Jun 2026 quarter. Full-year FY25 profit was $27.9 M. That loss is 63.1% of the quarter's revenue. The same quarter a year earlier earned $32.0 M. 8 of the last 12 reported quarters were loss-making. Jun 2026 profit was −$66.8 M, −308.6% on a year earlier. ## How much revenue does Alvotech make, and is it growing? Alvotech reported $106 M of revenue in the Jun 2026 quarter, −38.9% on the same quarter a year earlier. Over 4 years it has grown 96.3% a year on average. The last full year, FY25, came in at $589 M. The last four reported quarters add to $495 M. FY25 revenue was $589 M, +19.7% on the year before. Recent pace: the last four quarters grew −9.6% on average, against 96.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −12.1%, against +26.6% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Alvotech keep? Alvotech's operating margin was −11.1% in the Jun 2026 quarter, 21.5 percentage points lower than the same quarter a year ago. Across 5 years it has been between −551.8% and 14.3%. The latest quarter is within that range. Why the margin moved: operating margin changed −21.5 percentage points on the year while gross margin changed −6.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Alvotech's profit turning into cash? Alvotech's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $50.2 M of cash, against $27.9 M of profit. After $64.5 M of spending on assets, free cash was −$115 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Alvotech's cash go? Alvotech does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $151 M on assets over the last 3 years. Averaged over those years that is 8.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $151 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Alvotech's P/E ratio, and how does it compare with its own history? Alvotech's P/E is 58.0×, near the high end of its own history: higher than 84% of past readings. Its usual P/E (the middle reading) is 46.8×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Alvotech business getting better or worse? Alvotech's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Alvotech earn on its capital? Alvotech earned a ROE of −10% in FY25. Its return on capital used (ROIC) is 2.5 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 4.7% net margin and 0.40× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 4.7% net margin × 0.40× asset turnover × −5.23× leverage (assets divided by equity) ≈ −9.8% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 4.3% − 6.8% = −2.5 percentage points. The 6.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 4.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 1.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Alvotech have too much debt? Alvotech's net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from −3.86 in FY21 to −5.09 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Alvotech shareholding pattern? 4.5% of Alvotech's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Alvotech from balance-sheet trouble? For Alvotech, the Z-score is −1.00. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −1.00 is inside the danger zone, so the balance sheet is a real risk. ## How does Alvotech rank in its industry? 33.1 out of 100, rank 24 of 28 in Drug Manufacturers - Specialty & Generic, with 71% of the evidence available. Alvotech scores 33.1 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 24. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 6.1 + 5.4 + 11.2 + 10.4 = 33.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Alvotech compared with? Alvotech ranks 24 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 33.1 out of 100. 1. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) NBIX · turning · Most evidence points up · 81% evidence 66.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 34.4% · Profit 100% · Operating margin change 1 points · 83% evidence Capital efficiency 17.8/25 · ROCE 19.3% · Operating margin 22.2% · 76% evidence Valuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidence Relative strength 9.2/20 · Lead over its industry -4.9% · Lead over S&P 500 7% · 1 year 8.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25.8 + 17.8 + 13.8 + 9.2 = 66.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) ETON · leader · Most evidence points up · 64% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 81% · Profit n/a · Operating margin change 37.2 points · 62% evidence Capital efficiency 17.6/25 · ROCE 29.2% · Operating margin 35.8% · 76% evidence Valuation 8.8/20 · P/E 78.2× · PEG n/a · 15% evidence Relative strength 14.0/20 · Lead over its industry 37.9% · Lead over S&P 500 52.3% · 1 year 201.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.3 + 17.6 + 8.8 + 14 = 65.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) INDV · quiet · Evidence leans up · 71% evidence 63.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.5/35 · Revenue 13.5% · Profit 100% · Operating margin change 23.4 points · 83% evidence Capital efficiency 20.8/25 · ROCE 152.3% · Operating margin 46.9% · 76% evidence Valuation 10.3/20 · P/E 14.1× · PEG n/a · 15% evidence Relative strength 4.9/20 · Lead over its industry -13% · Lead over S&P 500 -2.1% · 1 year 15.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.5 + 20.8 + 10.3 + 4.9 = 63.5 · What this means: Earnings are strong; relative strength in its sector is -13% and the one-year return is 15.8%. 4. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) KNSA · leader · Evidence leans up · 71% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 58.7% · Profit 100% · Operating margin change -1.7 points · 83% evidence Capital efficiency 11.9/25 · ROCE 13.8% · Operating margin 11.2% · 76% evidence Valuation 9.0/20 · P/E 61× · PEG n/a · 15% evidence Relative strength 17.0/20 · Lead over its industry 40.9% · Lead over S&P 500 56.9% · 1 year 143.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 11.9 + 9 + 17 = 61.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) XERS · leader · Evidence leans up · 64% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 36.2% · Profit n/a · Operating margin change -0.7 points · 62% evidence Capital efficiency 11.5/25 · ROCE 16.5% · Operating margin 5.6% · 76% evidence Valuation 8.7/20 · P/E 83.3× · PEG n/a · 15% evidence Relative strength 18.6/20 · Lead over its industry 18.4% · Lead over S&P 500 32.5% · 1 year 39.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 11.5 + 8.7 + 18.6 = 59.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) BHC · leader · Evidence leans up · 71% evidence 59.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 10.1% · Profit -1220.4% · Operating margin change 9.1 points · 83% evidence Capital efficiency 12.6/25 · ROCE 13.5% · Operating margin 27.2% · 76% evidence Valuation 10.9/20 · P/E -1.7× · PEG n/a · 15% evidence Relative strength 18.3/20 · Lead over its industry 15.4% · Lead over S&P 500 29.8% · 1 year 22.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.5 + 12.6 + 10.9 + 18.3 = 59.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [BioCryst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/bcrx) BCRX · quiet · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 68.5% · Profit n/a · Operating margin change 26.9 points · 62% evidence Capital efficiency 18.1/25 · ROCE 112% · Operating margin 45.1% · 76% evidence Valuation 11.0/20 · P/E -6.6× · PEG n/a · 15% evidence Relative strength 4.5/20 · Lead over its industry -13.8% · Lead over S&P 500 -3.2% · 1 year 20.9% · 100% evidence · 3 of 12 weeks ahead Exact sum: 25.3 + 18.1 + 11 + 4.5 = 58.9 · What this means: Earnings are strong; relative strength in its sector is -13.8% and the one-year return is 20.9%. 8. [Amneal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amrx) AMRX · leader · Evidence leans up · 71% evidence 58.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 9.3% · Profit 100% · Operating margin change 2.8 points · 83% evidence Capital efficiency 14.8/25 · ROCE 17.1% · Operating margin 18.3% · 76% evidence Valuation 9.3/20 · P/E 35.1× · PEG n/a · 15% evidence Relative strength 13.1/20 · Lead over its industry 14.1% · Lead over S&P 500 27.5% · 1 year 77.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21 + 14.8 + 9.3 + 13.1 = 58.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) PAHC · breaking out · Evidence leans up · 81% evidence 58.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 17.2% · Profit 100% · Operating margin change 0.3 points · 83% evidence Capital efficiency 14.9/25 · ROCE 16.4% · Operating margin 10.6% · 76% evidence Valuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidence Relative strength 7.3/20 · Lead over its industry -22.7% · Lead over S&P 500 -13% · 1 year -14% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.1 + 14.9 + 11.8 + 7.3 = 58.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) UTHR · turning · Evidence leans up · 81% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.3/35 · Revenue 2.5% · Profit 5.6% · Operating margin change -6.2 points · 83% evidence Capital efficiency 20.0/25 · ROCE 21.2% · Operating margin 42.2% · 76% evidence Valuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidence Relative strength 11.7/20 · Lead over its industry -2.7% · Lead over S&P 500 9.4% · 1 year 34% · 100% evidence · 3 of 12 weeks ahead Exact sum: 14.3 + 20 + 9.2 + 11.7 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Liquidia Corporation](https://www.sectoralpha.in/us/stocks/lqda) LQDA · quiet · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative
12. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) VTRS · breaking out · Evidence leans up · 64% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Trulieve Cannabis Corp.](https://www.sectoralpha.in/us/stocks/trlv) TRLV · breaking out · Evidence leans up · 64% evidence 50.9 out of 100 Growth Capital Valuation Relative
14. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) ANIP · basing · Evidence leans up · 64% evidence 50.2 out of 100 Growth Capital Valuation Relative
15. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) TEVA · leader · Evidence leans down · 64% evidence 48.0 out of 100 Growth Capital Valuation Relative
16. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) ZTS · turning · Evidence leans down · 81% evidence 46.8 out of 100 Growth Capital Valuation Relative
17. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) HLN · quiet · Too little evidence to rank firmly · 56% evidence 45.8 out of 100 Growth Capital Valuation Relative
18. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) PRGO · breaking out · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
19. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) ELAN · turning · Evidence leans down · 71% evidence 43.9 out of 100 Growth Capital Valuation Relative
20. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) LNTH · turning · Evidence leans down · 81% evidence 43.6 out of 100 Growth Capital Valuation Relative
21. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) ALKS · quiet · Evidence leans down · 81% evidence 43.4 out of 100 Growth Capital Valuation Relative
22. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) HCM · breaking out · Too little evidence to rank firmly · 51% evidence 39.8 out of 100 Growth Capital Valuation Relative
23. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) PBH · quiet · Evidence leans down · 71% evidence 35.1 out of 100 Growth Capital Valuation Relative
24. Alvotech this page ALVO · breaking out · Most evidence points down · 71% evidence 33.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 6.1/35 · Revenue -11.9% · Profit -381.3% · Operating margin change -21.5 points · 83% evidence Capital efficiency 5.4/25 · ROCE 4.2% · Operating margin -11.1% · 76% evidence Valuation 11.2/20 · P/E -13.3× · PEG n/a · 15% evidence Relative strength 10.4/20 · Lead over its industry -12.3% · Lead over S&P 500 -1.2% · 1 year -20.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 6.1 + 5.4 + 11.2 + 10.4 = 33.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 25. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) HIMS · quiet · Most evidence points down · 71% evidence 27.6 out of 100 Growth Capital Valuation Relative
26. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) SUPN · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative
27. [Amylyx Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amlx) AMLX · leader · Too little evidence to rank firmly · 40% evidence 48.7 out of 100 Growth Capital Valuation Relative
28. Regencell Bioscience Holdings Limited RGC · breaking out · Too little evidence to rank firmly · 47% evidence 31.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - Specialty & Generic](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic), all 28 compared on one page. ## Which companies are close to Alvotech in size? Alvotech is the 26th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Perrigo Company plc, Xeris Biopharma Holdings, Inc. and Supernus Pharmaceuticals, Inc. Just below it: ANI Pharmaceuticals, Inc., Phibro Animal Health Corporation and Eton Pharmaceuticals, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) $2.2 billion
2. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) $1.9 billion
3. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) $1.6 billion
4. Alvotech $1.6 billion
5. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) $1.5 billion
6. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) $1.5 billion
7. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) $1.5 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Ultragenyx Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/rare) $1.6 billion · Biotechnology
2. [Yesway, Inc.](https://www.sectoralpha.in/us/stocks/yswy) $1.6 billion · Grocery Stores
3. Alvotech $1.6 billion
4. [Stepan Company](https://www.sectoralpha.in/us/stocks/scl) $1.6 billion · Specialty Chemicals
5. [Sprinklr, Inc.](https://www.sectoralpha.in/us/stocks/cxm) $1.6 billion · Software - Application

## What else do people ask about Alvotech? ### What were Alvotech's latest quarterly results? Alvotech reported revenue of $106 M and a net loss of $66.8 M for the Jun 2026 quarter. Revenue fell 38.9% and profit fell 308.6% compared with a year earlier. Earnings per share were −$0.22. The operating margin was −11.1%, 21.5 percentage points lower than a year earlier (as of 3 November 2026). ### What is Alvotech's market cap? Alvotech's market capitalisation is $1.6 B at a stock price of $4.54. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Alvotech performing? Alvotech's latest readings are below. In its latest quarter, revenue fell 38.9% and profit fell 308.6% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 15 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Alvotech's stock price go up? This page does not forecast Alvotech's stock price. What it shows instead: the stock price is $4.54. Its P/E of 58.0× is higher than 84% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Alvotech in its business cycle? Alvotech's FY25 operating margin was 14.1%, against a 5-year range of −551.8% to 14.3%: the middle of its own range, neither a peak nor a low. The latest quarter was −11.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Alvotech story? Biggest thing to watch: the P/E is higher than 84% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Alvotech a stock worth studying right now? What the numbers show: Alvotech's balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.